GW Pharmaceuticals reports loss despite success of CBD-based drug

CBD drug manufacturer GW Pharmaceuticals saw a significant net loss in the last quarter, despite growth and sales of its cannabis-derived pharmaceutical drugs going to plan.

The company reported a loss of $71.9m for the quarter ending 31st December 2018, compared with $61.8m for the same quarter in 2017.

...

Need help?

Contact a sales representative right now and don’t wait

Erik Galavis
+34 654 320 547
Email Erik

Restricted content. Do you want to read more?

Request report

Interested in buying?
Request more information

MORE INFO

Visit store

Check out our reports
available for purchase

VIEW REPORTS

Request a free sample of this report:

“ GW Pharmaceuticals reports loss despite success of CBD-based drug ”

    This file is not available, please fill the form to request your sample page:






    Buy report request information:

    “ GW Pharmaceuticals reports loss despite success of CBD-based drug ”






      CBD drug manufacturer GW Pharmaceuticals saw a significant net loss in the last quarter, despite growth and sales of its cannabis-derived pharmaceutical drugs going to plan.

      The company reported a loss of $71.9m for the quarter ending 31st December 2018, compared with $61.8m for the same quarter in 2017.

      ...

      Benefits of subscription plans:

      • Stay informed of any legal and market change in the sector that impacts your organization
      • Maximise resources by getting market and legal data analysis daily in one place
      • Make smart decisions by understanding how the regulatory and market landscape evolves
      • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

      Need help?

      Contact a sales representative right now and don’t wait

      Erik Galavis
      +34 654 320 547
      Email Erik